Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News MSD Isentress shows ‘comparable’ HIV RNA reduction to efavirenz

MSD Isentress shows ‘comparable’ HIV RNA reduction to efavirenz

27th July 2007

Merck, Sharp and Dohme (MSD) has presented the results of an ongoing 48-week phase II clinical trial of investigational orally-administered HIV integrase inhibitor Isentress (raltegravir).

The drug was administered to treatment-naive patients in conjunction with Viread (tenofovir) and Epivir (lamivudine), while the result showed the compound to result in reductions of HIV RNA to undetectable levels in 83 to 88 per cent patients.

MSD notes that this level is comparable to that seen in patients receiving Sustiva (efavirenz) in combination with the same compounds, where 87 per cent of patients exhibited reductions in HIV RNA to less that 50 copies per millilitre.

Furthermore, Isentress displayed a minimal impact on low-density lipoprotein serum cholesterol, serum triglycerides and the total cholesterol to high-density lipoprotein cholesterol ratio.

Martin Markowitz, clinical director of the Aaron Diamond Aids Research Centre, said: “In this study, the viral load reductions were sustained at week 48 in treatment-naive patients.”

He added that the findings of this trial were consistent with earlier efficacy and safety profiles for the compound exhibited at 24 weeks of treatment.

In February 2007, MSD presented positive phase III results for Isentress, with the compound showing greater antiretroviral activity than placebo when used together with optimised background therapy.

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.